Company Filing History:
Years Active: 2021
Title: Michael Zengerle: Innovator in PROTAC Technology
Introduction
Michael Zengerle is a notable inventor based in Ebertsheim, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of small molecule E3 ubiquitin ligase protein binding ligands. His work focuses on innovative treatments for proliferative, autoimmune, and inflammatory diseases.
Latest Patents
Zengerle holds a patent for "Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(l,3-thiazol-5-yl) benzene." This patent describes novel compounds that have utility in PROteolysis Targeted Chimeras (PROTACs). These compounds are designed to selectively induce degradation of the BRD4 protein, which is part of the bromo- and Extra-terminal (BET) family of proteins. The implications of this work are significant for advancing therapeutic strategies in various diseases.
Career Highlights
Michael Zengerle is affiliated with the University of Dundee, where he continues to push the boundaries of research in his field. His innovative approach to drug design and development has positioned him as a key figure in the scientific community.
Collaborations
Zengerle has collaborated with esteemed colleagues such as Alessio Ciulli and Kwok-Ho Chan. These partnerships have enhanced the scope and impact of his research, fostering advancements in the understanding of PROTAC technology.
Conclusion
Michael Zengerle's contributions to the field of medicinal chemistry and his innovative patent work exemplify the potential of PROTAC technology in treating complex diseases. His ongoing research at the University of Dundee continues to inspire advancements in therapeutic development.